Skip to content

Safety of remazolam combined with flurbiprofen ester in painless X-ray hysterosalpingography: a single-center, double-blind, prospective trial

Safety of remazolam combined with flurbiprofen ester in painless X-ray hysterosalpingography

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093113
Enrollment
Unknown
Registered
2024-11-28
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless X-ray hysterosalpingography

Interventions

Propofol group:All patients fasted for 8 h and abstained from drinking for 2 h. ECG, SBP, DBP and SpO2 were routinely monitored after admission to the angiography room. Peripheral venous access was es
Remazolam group:All patients fasted for 8 h and abstained from drinking for 2 h. ECG, SBP, DBP and SpO2 were routinely monitored after admission to the angiography room. Peripheral venous access was e

Sponsors

Liuzhou maternal and child health care hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Infertility patients aged between 20 and 45 years old were selected from the reproductive clinic of our hospital from October 2024 to March 2025. BMI 18.5 ~ 28 kg/m2; ASA grade ? ~ ?; Voluntary selection of painless X-ray salpingography; No specific underlying diseases; No history of mental illness; No serious medical disease; Know about this study, participate voluntarily, and sign the informed consent

Exclusion criteria

Exclusion criteria: ? Have a history of tubal surgery or uterine tubal congenital malformation; ?Combined with cardiovascular and respiratory diseases, serious heart, lung, liver, kidney insufficiency; ? A long history of smoking and alcoholism, allergy to contrast agents or propofol, benzodiazepines and other narcotic drugs; ?A history of alcohol or drug abuse; ? preoperative severe anemia; ? Mental disorders; ? Moderate to severe sleep apnea; ?Participation in other clinical trials within 1 month prior;

Design outcomes

Primary

MeasureTime frame
Mean arterial pressure;Intraoperative adverse reactions;Postoperative adverse reaction;Time of onset of sedation;Recovery time;Exit time;

Secondary

MeasureTime frame
Sedative was added > 3 times;Degree of lower abdominal pain after recovery (VAS score);Radiologist satisfaction;Anesthesiologist satisfaction;Patient satisfaction;

Countries

China

Contacts

Public ContactWen Xuejin

Liuzhou maternal and child health care hospital

262584527@qq.com+86 157 7829 5925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026